Technical Analysis for INAB - IN8bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | -3.95% | |
| Oversold Stochastic | Weakness | -3.95% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -9.59% | |
| Stochastic Buy Signal | Bullish | -9.59% | |
| Narrow Range Bar | Range Contraction | -9.59% | |
| Outside Day | Range Expansion | -9.59% |
| Alert | Time |
|---|---|
| Down 5% | about 5 hours ago |
| Down 3% | about 6 hours ago |
| Possible Inside Day | about 6 hours ago |
| 60 Minute Opening Range Breakdown | about 6 hours ago |
| 2x Volume Pace | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/10/2024
IN8bio, Inc. Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Treatment Of Cancer Stem Cell Transplantation Solid Tumor Cancers Acute Leukemia Regenerative Medicine Advanced Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.47 |
| 52 Week Low | 0.65 |
| Average Volume | 446,165 |
| 200-Day Moving Average | 1.13 |
| 50-Day Moving Average | 1.06 |
| 20-Day Moving Average | 1.11 |
| 10-Day Moving Average | 0.90 |
| Average True Range | 0.13 |
| RSI (14) | 38.65 |
| ADX | 23.09 |
| +DI | 19.21 |
| -DI | 24.24 |
| Chandelier Exit (Long, 3 ATRs) | 1.34 |
| Chandelier Exit (Short, 3 ATRs) | 1.18 |
| Upper Bollinger Bands | 1.59 |
| Lower Bollinger Band | 0.62 |
| Percent B (%b) | 0.2 |
| BandWidth | 87.70 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0415 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.90 | ||||
| Resistance 3 (R3) | 0.90 | 0.87 | 0.88 | ||
| Resistance 2 (R2) | 0.87 | 0.85 | 0.87 | 0.88 | |
| Resistance 1 (R1) | 0.84 | 0.84 | 0.83 | 0.84 | 0.87 |
| Pivot Point | 0.82 | 0.82 | 0.81 | 0.82 | 0.82 |
| Support 1 (S1) | 0.79 | 0.79 | 0.77 | 0.79 | 0.75 |
| Support 2 (S2) | 0.76 | 0.78 | 0.76 | 0.75 | |
| Support 3 (S3) | 0.73 | 0.76 | 0.74 | ||
| Support 4 (S4) | 0.73 |
